Recent Developments in Parkinson's and Lung Cancer Therapies
Biogen and Denali's experimental treatment for Parkinson's disease has not achieved its trial objectives, while Merck's lung cancer therapy appears to offer potential benefits.
Editorial Staff
1 min read
Updated 18 days ago
In a recent trial, Biogen and Denali announced that their experimental therapy for Parkinson's disease did not meet the expected goals, failing to slow the progression of the disorder.
On a more positive note, Merck's lung cancer treatment has shown promising results, indicating potential benefits for patients.
These updates highlight ongoing challenges and advancements in the pharmaceutical industry, particularly in the fields of neurodegenerative diseases and oncology.